- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00691184
Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis
A Double-Blind, Randomized, Parallel Design Study To Assess the Safety and Pharmacokinetics of Terbinafine Hydrogen Cloride (HCl) Nail Lacquer Applied for 28 Days in Patients With Onychomycosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a double-blind, randomized, parallel-design, placebo-controlled Phase 1 study comparing 10% Terbinafine HCl Nail Lacquer vs. Placebo Nail Lacquer (i.e., vehicle control). For comparative purposes, the study also included a contemporaneous assessment of 1% Lamisil® Cream (1% terbinafine HCl) and Lamisil® Tablets (terbinafine HCl labeled as 250 mg of terbinafine).
Forty (40) onychomycosis (Groups 1 and 2) and 16 tinea pedis (Group 3) patients were enrolled at 3 study centers. In Group 1, 10% Terbinafine HCl Nail Lacquer, and, in Group 2, its vehicle (0% terbinafine HCl), were applied topically by brushing on a dose volume of approximately 10 μL per nail twice daily for 28 days to each toenail and to 5 mm of adjacent skin. The patients visited the study center on Days 3, 7, 14, 21, and 28 for assessments of clinical signs and to obtain blood samples. In addition, a 24-hour urine sample was collected and assessed on Day 28 and Day 35. Fifty six (56) patients (20 in Group 1, 20 in Group 2, and 16 in Group 3) received a single oral dose of a 250 mg Lamisil® Tablet after a 7-day washout period.
For comparative purposes, the study also evaluated the local and systemic safety, and plasma levels of terbinafine, and its 3 major metabolites (i.e., desmethyl terbinafine, carboxybutyl terbinafine, and desmethyl carboxybutyl terbinafine) following administration of 1% Lamisil® Cream in comparison with 10% Terbinafine HCl Nail Lacquer. In Group 3, approximately 0.5 g of 1% Lamisil® Cream was applied twice a day for 7 days to the area of the foot affected with tinea pedis. The patients visited the study center on Day 3 and on Day 7 for assessments of clinical signs and collection of blood samples. A 24-hour urine sample was collected and assessed on Day 7 and Day 14.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Paramus, New Jersey, United States, 07652
- TKL Research Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients were required to meet all of the following criteria in order to be eligible for entry in the study:
- Were between 18 and 70 years of age, of any race and of either sex;
- Were in good general health as confirmed by a medical history and brief physical examination;
- Groups 1 and 2, presented with clinically diagnosed stable or exacerbating onychomycosis with more than 25 % involvement of one great toenail;
- For Group 3, had mild tinea pedis (mild tinea pedis was defined as mild erythema, mild scaling, cracking or fissuring, and mild burning or pruritus);
- For Groups 1 and 2, had at least five toenails with onycholysis;
- For Groups 1 and 2, a positive calcofluor (KOH) exam must have been obtained during Visit 1 from specimens taken from the affected great toenail;
- Signed a statement of informed consent;
- Were able to understand the requirements of the study, abide by the restrictions, and return for all of the required examinations;
- If female, met one of the following criteria: (a) had been post-menopausal for at least one year, or (b) had a hysterectomy or tubal ligation, or (c) was using oral/systemic contraceptives or an intrauterine device at least 28 days prior to study entry and throughout the study, or (d) agreed to use spermicide in combination with barrier methods of contraception throughout the study;
- Had 10 toes with nails that could be clipped to provide nail samples.
Exclusion Criteria:
Any of the following excluded a patient from participating in the study:
- Any missing toes;
- Known hypersensitivity to terbinafine or any of the excipients in the nail lacquer;
- Vital signs measurement that were clinically significantly outside the normal limits;
- Liver function test values more than two times the upper limit of normal or other clinical laboratory values, which were clinically significantly outside normal limits;
- Receipt of terbinafine tablets within 12 months or terbinafine cream or solution within six months prior to screening;
- Participation in a clinical trial for the systemic treatment of onychomycosis within the previous two months;
- Current treatment with rifampin, phenobarbital, phenytoin, carbamazepine, terfenadine, or digoxin;
- Prior treatment with an investigational drug within one month prior to study start;
- Diagnosis of psoriasis or history of psoriasis;
- Diagnosis of a serious concurrent disease that might prevent completion of the trial;
- Pregnancy (confirmed by pregnancy test), or plan to become pregnant within the study period or nursing;
- Inability to read, understand, or sign the informed consent form or the patient instructions for applying and removing the study formulations;
- Inability to apply the study medication;
- Onychomycosis patient unwilling to provide nail clippings;
- Inability to provide adequate blood sample;
- Use of any nail polish products or other nail cosmetic products within seven days prior to the start of treatment, or unwilling to discontinue use of these products during the course of this study.
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
0% Terbinafine HCl Nail Lacquer for 28 days.
|
0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
|
Experimental: Group 2
10% Terbinafine HCl Nail Lacquer.
|
10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
Other Names:
|
Active Comparator: Group 3
1% Lamisil® Cream
|
10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
Other Names:
|
Active Comparator: Group 4
Dose of 250 mg Lamisil® Tablets (Groups 1,2,3) at end of study.
|
Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary safety objective was to determine the safety of 10% Terbinafine HCl Nail Lacquer by assessing local and systemic adverse experiences, changes in vital signs, clinical laboratory test results, physical examinations, and electrocardiogram (ECG)
Time Frame: 28 Days
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine plasma levels of terbinafine and its metabolites after administration of 10% Terbinafine HCl Nail Lacquer to toenails, 1% Lamisil® Cream to the infected (i.e., tinea pedis) area of the foot and a single Lamisil® Tablet (250 mg) on Day 35.
Time Frame: 3, 7, 14, 21 and 28 days and Day 35
|
3, 7, 14, 21 and 28 days and Day 35
|
Collaborators and Investigators
Investigators
- Study Director: Ming Q Lu, MD., Ph.D., NexMed (U.S.A.), Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Foot Diseases
- Bacterial Infections and Mycoses
- Skin Diseases, Infectious
- Mycoses
- Skin Manifestations
- Tinea
- Dermatomycoses
- Nail Diseases
- Foot Dermatoses
- Pruritus
- Onychomycosis
- Tinea Pedis
- Onycholysis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antifungal Agents
- Terbinafine
Other Study ID Numbers
- NM-060-1001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis/Onycholysis and Tinea Pedis
-
University Hospitals Cleveland Medical CenterNovartisUnknown
-
National institute of SiddhaCompletedTinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are StudiedIndia
-
Taro Pharmaceuticals USATerminated
-
DermBiont, Inc.TerminatedInterdigital Tinea PedisDominican Republic
-
AmDermaAmDerma Pharmaceuticals, LLCCompletedInterdigital Tinea PedisUnited States
-
Ahmed A. H. AbdellatifUnknownFoot Infection Tinea PedisEgypt
-
William N HandelmanUnknown
-
Tinea PharmaceuticalsCompletedTinea Pedis | Tinea Cruris | Tinea CorporisUnited States, Puerto Rico, El Salvador, Belize, Honduras
-
Therapeutics, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Bausch & Lomb IncorporatedBausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States